| Symbol | ORKA |
|---|---|
| Name | ORUKA THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Address | 11080 CIRCLEPOINT ROAD,SUITE 140, WESTMINSTER, Colorado, 80020, United States |
| Telephone | +1 720 940-2200 |
| Fax | — |
| — | |
| Website | https://www.orukatx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000907654 |
| Description | Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Companys lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F). Additional info from NASDAQ: |
Goncalves Joana 🟡 adjusted position in 7.0K shares (2 derivative) of Oruka Therapeutics, Inc. (ORKA) at $112.56 Transaction Date: Aug 17, 2026 | Filing ID: 000079
Read moreQuinlan Paul T 🟡 adjusted position in 52.0K shares (2 derivative) of Oruka Therapeutics, Inc. (ORKA) at $111.14 ($6.8M) Transaction Date: Aug 14, 2026 | Filing ID: 000077
Read moreAgarwal Arjun 🟡 adjusted position in 10.0K shares (2 derivative) of Oruka Therapeutics, Inc. (ORKA) at $108.46 ($1.4M) Transaction Date: Aug 13, 2026 | Filing ID: 000075
Read more📋 PAUL QUINLAN (Officer) plans to sell 71K shares of Oruka Therapeutics, Inc. (at $108.12 each, total $7.7M) Filed: Aug 14, 2026 | ID: 008164
Read moreNew Form SCHEDULE 13G/A - Oruka Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001231919-26-000934 <b>Size:</b> 18 KB
Read moreNew Form SCHEDULE 13G/A - Oruka Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000905148-26-003735 <b>Size:</b> 36 KB
Read moreNew Form SCHEDULE 13G - Oruka Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001493215-26-000153 <b>Size:</b> 12 KB
Read moreOruka Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Read more(30% Negative) ORUKA THERAPEUTICS, INC. (ORKA) Reports Q3 2026 Financial Results
Read moreGoncalves Joana 🟡 adjusted position in 7.0K shares (2 derivative) of Oruka Therapeutics, Inc. (ORKA) at $87.25 Transaction Date: Jul 15, 2026 | Filing ID: 000073
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07474792 | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psori… | Phase2 | Plaque Psoriasis | Recruiting | 2026-03-19 | 2029-04-01 | ClinicalTrials.gov |
| NCT07449702 | An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis | Phase2 | Plaque Psoriasis | Recruiting | 2026-02-23 | 2030-07-01 | ClinicalTrials.gov |
| NCT07290569 | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psori… | Phase2 | Plaque Psoriasis | Active_Not_Recruiting | 2025-12-03 | 2028-12-01 | ClinicalTrials.gov |
| NCT07090330 | ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis | Phase2 | Plaque Psoriasis | Active_Not_Recruiting | 2025-07-18 | 2027-05-01 | ClinicalTrials.gov |
| NCT06944379 | ORKA-002-211 A Phase I Study to Evaluate ORKA-002 in Healthy Volunteers Followi… | Phase1 | Healthy Volunteers | Active_Not_Recruiting | 2025-05-19 | 2027-01-01 | ClinicalTrials.gov |
| NCT06698939 | ORKA-001 in Healthy Volunteers | Phase1 | Healthy Volunteers | Completed | 2024-12-19 | 2026-03-13 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07290569 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07290569 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07290569 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07290569 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 Maintenance Dose | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07090330 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07090330 |
| ORKA-001 Induction Dose | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07090330 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07290569 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07290569 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT06944379 |
| ORKA-002 | Other | Phase PHASE1 | Healthy Volunteers | ACTIVE_NOT_RECRUITING | NCT06944379 |
| ORKA-001 Maintenance Dose | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07090330 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07090330 |
| ORKA-001 Induction Dose | Other | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07090330 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07290569 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07290569 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06698939 |
| ORKA-001 | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06698939 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |
| Placebo | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-002 | Other | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07474792 |
| ORKA-001 Maintenance Dose | DRUG | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07090330 |
| ORKA-001 Induction Dose | DRUG | Phase PHASE2 | Plaque Psoriasis | ACTIVE_NOT_RECRUITING | NCT07090330 |
| ORKA-002 | DRUG | Phase PHASE2 | Plaque Psoriasis | NOT_YET_RECRUITING | NCT07474792 |
| Placebo | OTHER | Phase PHASE2 | Plaque Psoriasis | NOT_YET_RECRUITING | NCT07474792 |
| ORKA-001 | DRUG | Phase PHASE2 | Plaque Psoriasis | RECRUITING | NCT07449702 |